Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 64 of 103 for:    IVERMECTIN

Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03173742
Recruitment Status : Completed
First Posted : June 2, 2017
Last Update Posted : June 2, 2017
Sponsor:
Information provided by (Responsible Party):
Insud Pharma

Brief Summary:
Evaluation of the bioavailability and safety of one oral preparation containing fixed dose 18 mg ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) or two oral preparations containing fixed dose 18 mg ivermectin (IVM 36 MG TABLETS, LICONSA S.A., Spain) vs. reference dosing (weight based) of reference drug containing 6 mg ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil) in fasting conditions. A monocentric, open, randomized, single dose, three-period crossover trial in healthy volunteers.

Condition or disease Intervention/treatment Phase
Helminthiasis Drug: T1, T2, T3 Drug: T1,T3,T2 Drug: T2,T1,T3 Drug: T2,T3,T1 Drug: T3,T1,T2 Drug: T3,T2,T1 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA, Abbott Laboratórios do Brasil Ltda, Brazil)
Actual Study Start Date : March 2016
Actual Primary Completion Date : December 2016
Actual Study Completion Date : January 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Body Weight
Drug Information available for: Ivermectin

Arm Intervention/treatment
Experimental: T1, T2, T3

T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.

T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)

Drug: T1, T2, T3

T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.

T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)

Other Name: Treatment 1-2-3

Experimental: T1, T3, T2

T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.

T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)

Drug: T1,T3,T2

T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.

T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)

Other Name: Treatment 1-3-2

Experimental: T2,T1,T3

T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.

T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)

Drug: T2,T1,T3

T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.

T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)

Other Name: Treatment 2-1-3

Experimental: T2,T3,T1

T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.

T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)

Drug: T2,T3,T1

T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.

T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)

Other Name: Treatment 2-3-1

Experimental: T3,T1,T2

T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.

T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)

Drug: T3,T1,T2

T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.

T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)

Other Name: Treatment 3-1-2

Experimental: T3,T2,T1

T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.

T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)

Drug: T3,T2,T1

T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.

T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)

Other Name: Treatment 3-2-1




Primary Outcome Measures :
  1. Primary endpoint evaluated will be the PK parameters that define bioavailability in extent Ln [AUC0t] [ Time Frame: up to day 7 ]
    For group 3

  2. Primary endpoint evaluated will be the PK parameters that define bioavailability in extent in rate: Ln [Cmax] for each treatment in healthy volunteers with high weight (Group 3), calculated by means of a non-compartmental analysis. [ Time Frame: up to day 7 ]
    For group 3


Secondary Outcome Measures :
  1. Relative bioavailability for each treatment and for groups 1 and 2 will be evaluated with the PK parameters that define bioavailability in extent Ln [AUC0t] [ Time Frame: up to day 7 ]
    for group 1 and 2

  2. Relative bioavailability for each treatment and for groups 1 and 2 will be evaluated with the PK parameters that define bioavailability in extent in rate: Ln [Cmax] [ Time Frame: up to day 7 ]
    for group 1 and 2

  3. AUC0t (for non-compartmental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  4. AUC0∞ (for non-compartimental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  5. %AUC extra (residual area) (for non-compartimental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  6. tmax (for non-compartimental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  7. tlag (for non-compartimental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  8. Cl/F (for non-compartimental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  9. V/F (for non-compartimental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  10. t1/2 (for non-compartimental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  11. Ke (for non-compartimental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  12. MRT (for non-compartimental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  13. Cmax (for non-compartimental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  14. tlag (for compartimental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  15. ka (for compartimental analysis) [ Time Frame: D7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  16. Cl/F(for compartimental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  17. V/F (for compartimental analysis) [ Time Frame: up to day 7 ]
    PK profile for each treatment and each study group will be evaluated by means of a compartmental and non-compartmental analysis

  18. vital signs [ Time Frame: up to week 6 ]
    To asses safety and tolerability of the treatments

  19. laboratory analysis [ Time Frame: up to week 6 ]
    To asses safety and tolerability of the treatments

  20. Incidence of adverse events. [ Time Frame: up to week 6 ]
    To asses safety and tolerability of the treatments

  21. ECG [ Time Frame: up to week 6 ]
    To asses safety and tolerability of the treatments



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Caucasian subjects of either gender (male or female) with an age between 18 and 45 years (both inclusive).
  2. Medical history and physical examination with no relevant abnormal findings.
  3. No evidence of significant disease (organic or psychiatric) based on medical history, physical examination and complementary tests.
  4. Laboratory tests (complete hematology, clinical chemistry and urinalysis).
  5. Vital signs (systolic and diastolic blood pressure, heart rate and temperature) and electrocardiogram (ECG) record within normal range at screening.
  6. Participating female volunteers must use a reliable contraception method not containing hormones. List of accepted contraception method includes barrier methods (i.e. female/male condoms, diaphragms, spermicides), voluntary sterilization (female tubal occlusion) or non-medicated intrauterine devices (IUD) (i.e. inert or copper-releasing). Abstention is not considered a reliable contraception method.
  7. For female volunteers only: they must declare that they did not intend to become pregnant in the last month prior to screening and they do not intend to become pregnant during one month following the last study drug administration.
  8. Voluntary participation in the study, with written informed consent from the volunteer.
  9. The subject agrees to abstain from beverages or food containing methylxanthines (coffee, tea, cola, energy drinks, chocolate etc.), St John's Wort, vitamins, herbal remedies and chewing-gum for 48 hours prior to study drug administration and during each study period.
  10. The subject agrees to abstain from beverages or food containing grapefruit for 14 days prior to the first study drug administration and during the study (until last sample from the last period).

Exclusion Criteria:

  1. Background of allergy, idiosyncrasy or hypersensitivity to the study drugs or its excipients.
  2. Heavy consumer of stimulating drinks (>5 cups of coffee, tea, chocolate or cola drinks per day).
  3. Background of alcoholism or drug dependence in the last one year or daily consumption of alcohol > 40 gr/day for men or > 24 gr/day for women.
  4. Use of any medication within 15 days prior to taking the study treatment, including over-the-counter medications and medicinal plants (except for the use of paracetamol in short-term symptomatic treatments).
  5. Positive serology for hepatitis B, C or HIV.
  6. Background or clinical evidence of cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, hematological or neurological disease or other chronic diseases.
  7. Smokers or ex-smokers that gave up smoking less than 1 year prior to the study (day 1 of period I)
  8. Pregnancy or lactation status for female subjects.
  9. Participation in another clinical trial during the 3 months before starting the current trial.
  10. Donate blood in the 8 weeks prior to starting the study.
  11. Undergone major surgery during the previous 6 months.
  12. Clinically significant abnormal ECG with clinical significance in accordance with the CIM's clinical criterion
  13. Restrictive vegetarian diet
  14. Positive results to the breath alcohol test at screening or at Day -1
  15. Positive results to the drug abuse checks (urine test for: amphetamines, cannabinoids, opiates, benzodiazepines and cocaine) at screening or at admission on Day -1
  16. Epidemiological risk of being infected by Loa loa or other filariases, defined as those who have lived or have travelled to any of the following countries: Angola, Cameroon, Central Africa Republic, Chad, Congo, Democratic Republic of the Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria and Sudan.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Insud Pharma
ClinicalTrials.gov Identifier: NCT03173742     History of Changes
Other Study ID Numbers: MS842-101
2015-005690-20 ( EudraCT Number )
First Posted: June 2, 2017    Key Record Dates
Last Update Posted: June 2, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Helminthiasis
Parasitic Diseases
Ivermectin
Antiparasitic Agents
Anti-Infective Agents